Rizatriptan shows no advantage over placebo within first hour for vestibular migraine

Published Date: 29 May 2025

A rigorous randomized clinical trial of rizatriptan conducted by UCLA and Mayo Clinic researchers failed to outperform placebo in relieving the acute symptoms of vestibular migraine.

Read Full News

Latest News

US FDA Issues Recall Of Boston Scientific Heart Devices

Boston Scientific has issued an urgent recall to correct several heart devices after ⁠the U.S. Food and Drug Administration classified the action as its most serious recall,...

Delays in Visa Program Threaten Hundreds of Doctors

Prolonged HHS J-1 waiver backlogs leave hundreds of foreign-trained doctors facing departure this summer, threatening care in underserved areas, immigration attorneys warn.

AstraZeneca to Invest $405 Million in Britain After US-UK Pharma Deal

Prime Minister Keir Starmer said on Wednesday that Britain's biggest company AstraZeneca would invest 300 million pounds ($405 ⁠million) in the country, after pausing...

Europe Risks Falling Behind in Medicine Race, Roche CEO

Europe risks falling behind the US and China in pharma innovation because of bureaucracy and government policies threatening ⁠jobs, Roche CEO Thomas Schinecker warns.

US Health Regulators to Speed Up Medicare Device Coverage

U.S. health regulators announced a new program to speed up Medicare coverage for certain medical devices on ⁠Thursday, saying it would cut reimbursement timelines to as...

Germany Risks Missing Out on New Drugs, AstraZeneca CEO Says

AstraZeneca's CEO said Germany risks missing out on new drugs that ⁠the drugmaker plans to launch if the nation sticks with plans to keep pharmaceutical spending in check.

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Latest News

Boston Scientific has issued an urgent recall to correct several heart devices after ⁠the U.S. Food and Drug Administration classified the action as its most serious recall,...

Prolonged HHS J-1 waiver backlogs leave hundreds of foreign-trained doctors facing departure this summer, threatening care in underserved areas, immigration attorneys warn.

Prime Minister Keir Starmer said on Wednesday that Britain's biggest company AstraZeneca would invest 300 million pounds ($405 ⁠million) in the country, after pausing...

Europe risks falling behind the US and China in pharma innovation because of bureaucracy and government policies threatening ⁠jobs, Roche CEO Thomas Schinecker warns.

U.S. health regulators announced a new program to speed up Medicare coverage for certain medical devices on ⁠Thursday, saying it would cut reimbursement timelines to as...

AstraZeneca's CEO said Germany risks missing out on new drugs that ⁠the drugmaker plans to launch if the nation sticks with plans to keep pharmaceutical spending in check.

News All Time

The Golden Handcuffs of Private Equity

Private equity firms are increasingly buying up smaller medical practices. Sometimes for the better, and sometimes not.

New Book Spotlights Medicine’s Emotional Side

A new anthology, Where It Hurts: Dispatches from the Emotional Frontlines of Medicine, explores how doctors process the day-to-day challenges of their careers.

Novel imaging approach may improve treatment for spinal cord injuries

Northwestern Medicine investigators have developed a new imaging approach to more accurately assess blood flow in the spinal cord, a method that could be used to better inform treatment for neurological diseases and injuries, ...

Tirzepatide may only temporarily suppress brain 'food noise' activity

A rare glimpse into the brain activity of a patient with obesity and loss of control eating on tirzepatide, marketed as Mounjaro and Zepbound, revealed that the medication suppresses signaling in the brain's "reward center" ...

Supercomputer simulation is changing how we study the brain

Harnessing the muscle of one of the world's fastest supercomputers, researchers have built one of the largest and most detailed biophysically realistic brain simulations of an animal ever.

AI tool creates digital twins of patients to predict their future health

A new artificial intelligence tool that can create virtual representations of patients and predict individual health trajectories has been hailed a potential gamechanger for the clinical trial sector.

New tool predicts graft failure after kidney transplant

Researchers at The Johns Hopkins Medicine say they have developed a new electronic medical records-based tool that should help doctors predict which patients are most at risk of losing a transplanted kidney graft.

How are patients using health care chatbots? Study finds some 'eye-openers'

A health care chatbot can be a patient's first point of contact for some sensitive conversations from mental health to billing, a new CU Anschutz study has found.

New study reveals high rates of fabricated and inaccurate citations in LLM-generated mental health research

A new study published in the journal JMIR Mental Health by JMIR Publications highlights a critical risk in the growing use of Large Language Models (LLMs) like GPT-4o by researchers: the frequent fabrication and inaccuracy ...

A unified model of memory and perception: How Hebbian learning explains our recall of past events

A collaboration between SISSA's Physics and Neuroscience groups has taken a step forward in understanding how memories are stored and retrieved in the brain. The study, recently published in Neuron, shows that distinct perceptual ...

Malaria rapid diagnostic test 'not fit for purpose,' international study claims

An international study published in the Malaria Journal claims that a widely used test for detecting malaria is delivering too many inaccurate false-negative results and is "not fit for purpose."

Ovarian tissue preservation enables future fertility for young woman with cancer

In patients of reproductive age who have cancer, fertility preservation for potential children in the future should be a high priority. A practice article published in the Canadian Medical Association Journal describes the ...

Simple test brings clarity and hope for families with inherited neuropathy

A new, inexpensive urine test that measures two sugar alcohols, sorbitol and xylitol, is making it easier, faster, and far less expensive to identify a common inherited nerve disorder called SORD-related neuropathy. The test, ...

Would you put period blood on your face? What science says about 'menstrual masking'

In the ever-evolving world of beauty trends, few have sparked as much debate—and discomfort—as "menstrual masking." This is the practice of applying menstrual blood to the skin, usually the face, as a form of DIY skincare.

Reaching the unreachable: Endoscopy technique opens route to deep lung tumors

Researchers at the University of Osaka have engineered a novel technique, balloon-assisted bronchoscope delivery (BDBD), to guide endoscopes to small, early-stage lung cancers hidden deep within the periphery of the lungs.

Healing the heart after a heart attack with a biodegradable patch

A new patch developed by Texas A&M University researcher Dr. Ke Huang may offer a way to help the heart heal after a heart attack. The patch uses a unique microneedle system to deliver a therapeutic molecule directly to damaged ...

Recommended News For You

Shorter, less intense regimen still effective for HPV-linked throat cancer, study shows

Adopted cancer cells and the effects of their presence.

Combo Therapy Boosts Early CML Response but Not Long Term

Pickleball program boosts health and wellness for cancer survivors, study finds

Sustained reduction found in prostate cancer mortality with prostate-specific antigen screening

"We Caught It Early": Advantage or Disadvantage?

From 40 to 74, the US Preventive Services Task Force advises every two years for screening mammography.

Recommended Articles For You

Screening Efficacy, Molecular Precision, and Therapeutic Revolutions in Lung Cancer 2025 

Everything You Need To Know About Melanoma Choroid: Causes, Symptoms, and Treatment 

Uncovering the Hidden Picture: Using Ultrasound to Diagnose Breast Cancer 

The Significance of APTT Blood Test Results for Detecting Coagulation Disorders 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care

2.

FDA approves Blenrep for relapsed or refractory multiple myeloma

3.

X-ray and radar technology combined to reduce cancer screening risks

4.

Extended Maintenance with Imatinib Enhances Disease-Free Survival in High-Risk GIST.

5.

Researchers discuss HER2-low and HER2-zero in breast cancer

1.

Understanding Mesenteric Masses: Symptoms, Diagnosis, and Treatment Options

2.

Liposomal Doxorubicin and Mitomycin in Modern Cancer Treatment

3.

The New Era of Oncology: Key Updates and Clinical Insights

4.

HIPEC in Platinum-Sensitive Ovarian Cancer: A Promising Yet Controversial Option

5.

Theranostics and Radioligand Therapy: Precision Cancer Care with Targeted Radionuclides

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial

2.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I

3.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

4.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II

5.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot